Clinical Trial Update: Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients [Phase 2]

View source ↗

Summary

The update indicates that the Phase 2 safety, tolerability, and efficacy study of CPI-613 in cancer patients has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• CPI-613 (devimistat)

Snippet

Sponsor: Cornerstone Pharmaceuticals | Conditions: Cancer | Phase 2 | Status: TERMINATED